Introduction
The human genome contains 57 genes encoding cytochrome P450 (CYP) enzymes, of which 7 are Type I and 50 are Type II. Type I enzymes, found in the mitochondria, receive electrons from NADPH through ferredoxin reductase; whereas, Type II enzymes, located in the endoplasmic reticulum, receive electrons from NADPH through a single protein, cytochrome P450 oxidoreductase (POR). Type II P450 enzymes perform a variety of functions: 23 are involved in metabolism of steroid, fatty acids, eicosanoids, and vitamins, 12 havè`o rphan'' classiˆcation, and 15 catalyze drug metabolism. 1) These drug-metabolizing Type II P450 enzymes are the primary enzymes, metabolizing more than 80z of current prescription drugs.
2) Single nucleotide polymorphisms (SNPs) in some P450 enzymes have signiˆcant in‰uence on drug metabolic rates which are critical for drugs with narrow therapeutic indices, such as warfarin and phenytoin. 3, 4) However, unlike polymorphisms in a P450 enzyme which can only aŠect the expression level, activity, or structure of that particular enzyme, polymorphisms in a universal P450 enzyme cofactor could in‰uence the metabolism of all drugs catalyzed by the P450 enzymes. Cytochrome P450 oxidoreductase (NP_000932.3) is a co-factor for all microsomal Type II P450 enzymes. 5) POR transfers electrons from NADPH to a microsomal Type II P450 enzyme for oxidation of its substrates. Since there is no other electron donor for the microsomal Type II P450 system, POR is essential for drug metabolism.
The necessity of POR has been supported in the mouse by targeted gene disruption during development giving rise to diŠerent embryonically lethal phenotypes. 6 ) Liver speciˆc conditional knock-out studies have shown reproductively normal mice, but with a severely diminished capacity for hepatic drug metabolism and accumulation of hepatic lipids. 7, 8) The human POR gene is quite polymorphic. Currently, the NCBI dbSNP database has reported ¿320 SNPs in the 32-kb POR gene. 9) Genetic polymorphisms in the POR gene have recently been associated to an autosomal recessive genetic disease,``P450 oxidoreductase deˆciency'' [10] [11] [12] [13] [14] [15] with clinical phenotypes of ambiguous genitalia, congenital adrenal hyperplasia, the skeletal malformation Antley-Bixler syndrome, and polycystic ovary syndrome. However, it is unclear whether or not genetic polymorphisms in the POR gene in the general population aŠect P450-catalyzed drug metabolism. Here we report the identiˆcation of 34 SNPs in the exons and surrounding introns of the POR gene in 100 human liver samples. Nine of these SNPs are novel.
Materials and Methods
DNA samples were isolated from 100 liver tissue lysates purchased from XenoTech (Lenexa, Kansas, USA) with ChargeSwitch } gDNA Mini Tissue kit (Invitrogen, Carlsbad, California, USA). This cohort consisted of samples from 77 Caucasians, 10 AfricanAmericans, 10 Hispanics, and 3 Asians. The livers were initially harvested for transplantation purposes, but were not utilized and subsequently donated for research for varying reasons. Target DNA molecules were ampliˆed by PCR. Forward and reverse primers were designed by DS Gene Software (Accelrys, Cambridge, UK). The primer sequences and PCR product sizes are listed in Table 1 . The selected primer sequences were synthesized by Integrated DNA Technologies (Coralville, Iowa, USA). PCR reactions were performed at cycling conditions of 959 C for 10 min, 40 cycles of 949 C for 15 seconds, 609 C for 30 seconds, and 729 C for 45 seconds, followed by 729 C for 5 min, with Go Taq Polymerase purchased from Promega (Madison, Wisconsin, USA). PCR products were puriˆed with the Pre-sequencing Kit provided by USB, (Cleveland, Ohio, USA). DNA sequencing reactions were carried out using BigDye Terminator V 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster city, California, USA) with the forward primers. For dye terminator removal, PERFORMA } DTR Gel Filtration cartridges (Edge BioSystems, Gaithersburg, Maryland, USA) were used, and sequences were analyzed with a 3130 DNA Analyzer (Applied Biosystems, Foster City, California, USA).
Results and Discussion
Genetic polymorphisms were identiˆed by sequencing PCR amplicons from the exons and approximately 100 bp ‰anking intronic sequences. The sequences were compared to the reference contig for human POR from the NCBI database (NT_007933.14). We found 34 SNPs in the exons and the surrounding introns of the POR gene in the 100 human liver samples, including 9 novel SNPs ( Table 2) . As expected, we did not observe any of the missense or frameshift mutations (T142A, Q153R, Y181D, M263V, A287P, R457H, Y459H, V492E, G539R, L565P, C569Y, Y578C, V608F, R616X, F646del, I444fsX449, and L612W620delinsR) which have been associated with POR deˆciency. [10] [11] [12] [13] Three novel nonsynonymous SNPs, 817733GÀC (K49N), 848661CÀA (L420M), and 849577TÀC (L577P) were found with minor allele frequencies of 0.005, 0.045, and 0.020, respectively. Six other novel SNPs were observed in intron 7 (846457GÀA, 846539CÀT), intron 12 (848803TÀA, 848832CÀT), and the 3?-UTR (850151GÀA, 850197GÀA) all with minor allele frequencies less than 0.010. Five silent mutations (G5G, T29T, P129P, S485S, and S572S) and a missense mutation (A503V) were conˆrmed in these liver samples with similar allele frequencies reported in the NCBI dbSNP database ( Table 2) .
Based on the crystal structure of rat POR protein, 16) which is 92z identical to the human POR, we predicted the locations of all identiˆed POR polymorphisms with respect to the diŠerent functional domains. We found one sample with a heterozygous GÀC transversion at 817733, resulting in a missense mutation K49N. This missense mutation is located in the amino-terminal tail of POR. This terminal region is responsible for anchoring POR into the endoplasmic reticulum or into the plasma membrane 17) and is important for proper electron transfer function. 18, 19) We found nine heterozygotes for a CÀA transversion at 848661 which results in a leucine to methionine change at amino acid 420 (L420M). This amino acid lies in the connecting domain. This domain is responsible for e‹cient electron transport. 16) Four heterozygotes were found with a TÀC transition at 849577, leading to an amino acid change L577P, which is located in the NADPH-binding domain of POR. 16) An amino acid substitution in this region could potentially aŠect binding kinetics for NADPH. Once NADPH releases its electrons, it becomes NADP , an unusable metabolite. POR must release NADP in order to bind NADPH for electron cycling to continue. Neighboring mutations (G539R, L565P, C569Y, Y578C, and V608F) in the NADPH binding domain have been identiˆed in POR deˆciency patients. [10] [11] [12] [13] All these mutations showed signiˆcantly reduced POR activity in cytochrome c reduction assays.
12) Twenty-nine samples were heterozygous for a CÀA transversion at 849282 (rs1057868) and 6 were homozygous. This A503V mutation wasˆrst uploaded to the NCBI dbSNP database in 2000, and was conrmed by the NIEHS Environmental Genome Project in 2006. This mutation occurs in the FAD binding domain of POR. An in vitro experiment showed that cytochrome c reduction by POR carrying this mutation was decreased 31z compared to wild type. 12) The functional in‰uence of the POR mutations identiˆed in this paper on drug-metabolizing P450 enzyme activities has been established in this set of human liver samples. Our results indicate that genetic polymorphisms in the POR gene indeed in‰uence P450-catalyzed drug metabolism. The data will be published in another place.
